Publications by authors named "E H Shreck"
Introduction: Active surveillance (AS) is the standard for very low- and low-risk prostate cancer. Although risk factors for pathologic reclassification while on AS have been identified, results are mixed for non-Hispanic Black (NHB) and Hispanic ethnicity. We aim to further explore how race and ethnicity may be affecting AS participation and outcomes in a primarily urban, diverse, and vulnerable population.
View Article and Find Full Text PDFBackground: Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between patients with and without prior intravesical Bacillus Calmette-Guerin (BCG), who received ICI for aUC, hypothesizing that prior intravesical BCG would be associated with worse outcomes.
Patients And Methods: We performed a retrospective cohort study across 25 institutions in US and Europe.
Article Synopsis
- The study aims to compare the clinical outcomes of advanced urothelial carcinoma patients treated with immune checkpoint inhibitors, focusing on those who had prior radical surgery or radiation therapy versus those who did not.
- Researchers analyzed data from 562 patients across multiple institutions, assessing response rates, progression-free survival, and overall survival based on prior treatments.
- Results showed that patients in the second-plus-line treatment group with previous radical surgery had significantly better outcomes compared to those without, but this difference was not observed in the first-line setting.
Introduction: We sought to determine if outcomes of Bacillus Calmette-Guerin (BCG) therapy in patients with non-muscle-invasive bladder cancer (NMIBC) vary by race.
Methods: A retrospective chart review was conducted on 149 patients treated with BCG for intermediate- and high-risk NMIBC between 2001 and 2018, and who were followed up for cancer recurrence through March 2019.The primary outcomes were disease-free survival (DFS), low-grade disease-free survival (LGDFS), high-grade disease-free survival (HGDFS), and progression-free survival (PFS) at five years.
Article Synopsis
- The study aimed to compare clinical outcomes between patients with locally advanced or metastatic urothelial carcinoma in the upper and lower urinary tract receiving immune checkpoint inhibitors.
- A retrospective analysis included 746 patients and found that those with upper urinary tract cancer had similar objective response rates, overall survival, and progression-free survival compared to those with lower urinary tract cancer.
- However, patients with mixed-histology upper urinary tract cancer exhibited lower treatment response and shorter progression-free survival compared to their lower tract counterparts, highlighting the need for further research on patient selection for immunotherapy.